ATI Physical Therapy (ATIP) Q2 2024 earnings summary

Executive summary

• Achieved strong year-over-year growth in Q2 2024, with increased patient demand, higher visit volumes, improved rate per visit, and operational execution driving results.

• Net patient revenue increased 10.1% year-over-year to $172.8M for Q2 2024.

• Adjusted EBITDA rose to $16.6M in Q2 2024 from $9.3M in Q2 2023, with margin improving to 8.8% from 5.4% year-over-year.

• Net loss narrowed to $2.6M in Q2 2024 from $21.7M in Q2 2023, reflecting higher revenues and lower corporate costs.

• The company continues to face substantial doubt about its ability to continue as a going concern due to ongoing negative cash flows and liquidity constraints.

Financial highlights

• Net revenue for Q2 2024 was $188.1 million, up 9.2% from Q2 2023.

• Salaries and related costs rose 7.6% to $102.5 million, mainly due to increased staffing and wage inflation.

• SG&A expenses dropped 36.9% to $23.1 million, reflecting lower transaction and insurance costs.

• Net loss for the first half of 2024 was $16.1 million, a 65.8% improvement from $47.0 million in the prior year period.

• Cash and cash equivalents stood at $33.0 million as of June 30, 2024, with no available capacity under the revolving credit facility.

Outlook and guidance

• Q3 2024 net revenue expected between $180 million and $190 million, representing 1% to 7% year-over-year growth.

• Adjusted EBITDA guidance for Q3 is $9 million to $14 million, with the midpoint implying 22% growth and a 6% margin.

• Management is focused on increasing clinical staffing, improving productivity, controlling costs, and boosting visit volumes and rates.

• The company is seeking additional liquidity in 2024 to fund operations, capital expenditures, and interest payments.

• There is no assurance that planned initiatives or additional funding will be successful; bankruptcy risk remains.